← Leaderboards
Nigel S Key
Univ Of North Carolina Chapel Hill
$14,906,926
Attributed
$25,303,953
Total exposure
12
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,274,465 · 13
By mechanism
R01$10,101,969 · 5
P01$7,772,592 · 2
U01$7,568,452 · 1
T32$6,827,387 · 1
M01$4,065 · 4
Top collaborators
- Nigel Mackman11 shared
- Rafal L Pawlinski11 shared
- Kenneth I Ataga4 shared
- Jason V Baker4 shared
- Russell P Tracy4 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Nigel Mackman$23,794,157
- Seth A Berkowitz$9,978,614
- Rafal L Pawlinski$8,739,544
- Yun Li$11,441,630
- Aaron L Fogelson$5,408,600
Others in their field
Top investigators on “Hematology”
- Ronald T Mitsuyasu · University Of California Los Angeles$101,687,366
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$82,226,988
- Stanley Carlton Ahalt · Univ Of North Carolina Chapel Hill$78,409,067
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
Research focus
HematologyCoagulation ProcessThromboplastinMouse ModelResearch TrainingPathway InteractionsBloodHuman SubjectMediatingComplexVenous ThrombosisBlood PlateletsClinical ResearchWhole BloodVenousThrombinThrombusOrganBlood CoagulationThromboembolismPreventFibrin Fragment DMonocytePrograms
Grant awards (63)
Mechanisms of venous thrombosis and renal dysfunction in sickle trait$697,943
R01 · FY2025 · HL · contact PI
Research Training in Hematology at UNC Chapel Hill$373,631
T32 · FY2025 · HL · contact PI
Mechanisms of venous thrombosis and renal dysfunction in sickle trait$720,846
R01 · FY2024 · HL · contact PI
Mechanism of sickle cell disease-specific venous thromboembolism$647,758
R01 · FY2024 · HL
Research Training in Hematology at UNC Chapel Hill$484,006
T32 · FY2024 · HL · contact PI
Mechanism of sickle cell disease-specific venous thromboembolism$660,978
R01 · FY2023 · HL
Research Training in Hematology at UNC Chapel Hill$458,105
T32 · FY2023 · HL · contact PI
Mechanism of sickle cell disease-specific venous thromboembolism$660,978
R01 · FY2022 · HL
Research Training in Hematology at UNC Chapel Hill$446,893
T32 · FY2022 · HL · contact PI
Mechanism of sickle cell disease-specific venous thromboembolism$673,465
R01 · FY2021 · HL
Fibrinolysis Evaluation in A-TREAT (âFEATâ Study)$388,749
R01 · FY2021 · HL · contact PI
Research Training in Hematology at UNC Chapel Hill$235,883
T32 · FY2021 · HL · contact PI
Fibrinolysis Evaluation in A-TREAT (âFEATâ Study)$391,250
R01 · FY2020 · HL · contact PI
Research Training in Hematology at UNC Chapel Hill$303,041
T32 · FY2020 · HL · contact PI
Fibrinolysis Evaluation in A-TREAT (âFEATâ Study)$398,365
R01 · FY2019 · HL · contact PI
Research Training in Hematology at UNC Chapel Hill$394,562
T32 · FY2019 · HL · contact PI
Research Training in Hematology at UNC Chapel Hill$384,173
T32 · FY2018 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,481,743
U01 · FY2017 · HL · contact PI
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$433,273
R01 · FY2017 · HL
Research Training in Hematology at UNC Chapel Hill$373,096
T32 · FY2017 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,481,743
U01 · FY2016 · HL
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$667,919
R01 · FY2016 · HL
Research Training in Hematology at UNC Chapel Hill$124,743
T32 · FY2016 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,459,516
U01 · FY2015 · HL
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$554,349
R01 · FY2015 · HL
Research Training in Hematology at UNC Chapel Hill$353,661
T32 · FY2015 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,452,109
U01 · FY2014 · HL
Targeted anticoagulant therapy to reduce inflammation in treated HIV disease$638,645
R01 · FY2014 · HL
Research Training in Hematology at UNC Chapel Hill$312,574
T32 · FY2014 · HL · contact PI
Targeted Anticoagulant Therapy for Sickle Cell Disease$1,693,341
U01 · FY2013 · HL
Research Training in Hematology at UNC Chapel Hill$338,588
T32 · FY2013 · HL · contact PI
Mechanisms of Venous Thromboembolism in Cancer$546,028
R01 · FY2012 · HL
Research Training in Hematology at UNC Chapel Hill$302,383
T32 · FY2012 · HL · contact PI
Mechanisms of Venous Thromboembolism in Cancer$35,855
R01 · FY2012 · HL
Mechanisms of Venous Thromboembolism in Cancer$488,797
R01 · FY2011 · HL
Research Fellowships in Hematology/Oncology$223,980
T32 · FY2011 · HL · contact PI
Mechanisms of Venous Thromboembolism in Cancer$493,735
R01 · FY2010 · HL
Research Fellowships in Hematology/Oncology$367,607
T32 · FY2010 · HL · contact PI
Mechanisms of Venous Thromboembolism in Cancer$505,706
R01 · FY2009 · HL
Research Fellowships in Hematology/Oncology$364,613
T32 · FY2009 · HL · contact PI
Mechanisms of Venous Thromboembolism in Cancer$497,330
R01 · FY2008 · HL
Research Fellowships in Hematology/Oncology$361,658
T32 · FY2008 · HL · contact PI
Research Fellowships in Hematology/Oncology$361,658
T32 · FY2007 · HL · contact PI
RESEARCH FELLOWSHIPS IN HEMATOLOGY/ONCOLOGY$262,532
T32 · FY2005 · HL
NEW THERAPIES FOR HEMOPHILIA$1,458,784
P01 · FY2004 · HL
PREVENT: Prevention of Recurrent Venous Thromboembolism$3,696
M01 · FY2004 · RR
Catheter Directed Thrombolytic Therapy in Deep Vein Thrombosis$369
M01 · FY2004 · RR
NEW THERAPIES FOR HEMOPHILIA$1,425,906
P01 · FY2003 · HL
NEW THERAPIES FOR HEMOPHILIA$5,939
P01 · FY2003 · HL
NEW THERAPIES FOR HEMOPHILIA$1,388,152
P01 · FY2002 · HL
Tissue factor in hemophilia$267,360
P01 · FY2002 · HL
PREVENT: PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM$0
M01 · FY2002 · RR
ENDOTHELIAL CELLS IN HOMOCYSTINURIA$0
M01 · FY2002 · RR
ENDOTHELIAL CELLS IN HOMOCYSTINURIA$0
M01 · FY2002 · RR
PREVENT: PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM$0
M01 · FY2002 · RR
NEW THERAPIES FOR HEMOPHILIA$1,354,933
P01 · FY2001 · HL
Tissue factor in hemophilia$267,360
P01 · FY2001 · HL
ENDOTHELIAL CELLS IN HOMOCYSTINURIA$0
M01 · FY2001 · RR
PREVENT: PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM$0
M01 · FY2001 · RR
NEW THERAPIES FOR HEMOPHILIA$1,336,798
P01 · FY2000 · HL
Tissue factor in hemophilia$267,360
P01 · FY2000 · HL
ENDOTHELIAL CELLS IN HOMOCYSTINURIA$0
M01 · FY2000 · RR
PREVENT: PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM$0
M01 · FY2000 · RR